Prevail Therapeutics Inc. announced three upcoming poster presentations at the Alzheimer's Association International Conference (AAIC) 2020. These data underscore the robust preclinical evidence in support of Prevail's AAV-based gene therapy approach, and highlight the Company's strategy to validate these data in the planned PROCLAIM clinical trial evaluating PR006 for the treatment of frontotemporal dementia patients with GRN mutations (FTD-GRN). The conference will be held virtually July 27-31, 2020.